| Code | CSB-RA006044MB6HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to Emactuzumab, designed for research targeting colony-stimulating factor 1 receptor (CSF1R). CSF1R is a cell surface tyrosine kinase receptor that regulates the differentiation, proliferation, and survival of mononuclear phagocytic cells, including macrophages, monocytes, and osteoclasts. Upon binding its ligands CSF1 and IL-34, CSF1R activates signaling pathways critical for macrophage function and tissue homeostasis. Aberrant CSF1R signaling is implicated in various pathological conditions, including tumor-associated macrophage infiltration in solid tumors, inflammatory disorders, and certain neurodegenerative diseases. Elevated CSF1R expression correlates with poor prognosis in multiple cancer types.
Emactuzumab is a humanized IgG1 monoclonal antibody that binds CSF1R and blocks ligand-induced receptor activation, leading to reduced macrophage survival and altered tumor microenvironment dynamics. This biosimilar antibody serves as a valuable research tool for investigating CSF1R-mediated signaling pathways, exploring macrophage biology, studying tumor-immune interactions, and evaluating therapeutic strategies targeting the CSF1/CSF1R axis in oncology and inflammatory disease models.
There are currently no reviews for this product.